Chronic stress and mental disorders in patients with systemic scleroderma: Results of an interdisciplinary study


Cite item

Full Text

Abstract

Aim. To analyze of the prevalence of stressful factors and mental disorders (MDs), as well as their clinical psychopathological and clinical psychological characteristics to improve the comprehensive diagnosis and treatment of systemic scleroderma (SSD). Subjects and methods. Examinations were performed in 110 patients (predominantly women (n=97 (88.2%); mean age, 49.9±2.47 years) with a documented diagnosis of SSD (its mean duration, 7.25±0.42 years). 62 (56.4%) patients had limited SSD, 36 (32.7%) had diffuse SSD, and 12 (10.9%) had overlap syndrome. The disease was rapidly and slowly progressive in 33 (30%) and 77 (70%) patients, respectively. Oral glucocorticosteroids were used in 99 (90%) patients included in the study, cytotoxic drugs in 66 (60%), plaquenil in 33 (30%); 8 (7%) patients were treated with the biological agent rituximab. All the patients were examined by a psychologist and a psychiatrist. The psychopathological diagnosis of MD was made during a semistructured interview in accordance with the ICD-10 criteria. The Montgomery-Asberg depression and Hamilton anxiety rating scales were used to evaluate the severity of depression and anxiety, respectively. All patients underwent a clinical and psychological examination, including tests assessing memory, attention, and logical thinking, as well as projective techniques. Results. MDs were detected in 91 (83%) patients with SSD. There was a preponderance of depressive disorders in 74 (67.3%) patients: chronic (dysthymia in 33 (30%) patients)) and recurrent (recurrent depressive disorder in 34 (31%)) depressions. Cognitive impairment (CI) of varying severities was diagnosed in 100% of the patients. Schizotypal personality disorder was stated in 44 (40%) patients. 90% of patients were found to have chronic psychic traumas mainly as parental deprivation in childhood (in children less than 11 years of age). 76.7% of the SSD cases developed recurrent episodes of depression in the presence of long-term MD or had a history of the episodes. There was no relationship of MD to gender, age, duration of SSD and its individual clinical manifestations. The nature of SSD treatment did not affect the frequency and spectrum of MD. Conclusion. MDs, predominantly chronic and recurrent depression, and CI are characteristic of most SSD patients. Multiple chronic stressful factors, both previous SSD and those over time, have commonly an impact on the mental health of patients with SSD

About the authors

O F Seravina

ФГБУ «Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России

Москва, Россия

T A Lisitsyna

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»

Москва, Россия

M N Starovoytova

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»

Москва, Россия

O V Desinova

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»

Москва, Россия

O B Kovalevskaya

ФГБУ «Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России

Москва, Россия

D Yu Veltishchev

ФГБУ «Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России

Москва, Россия

References

  1. Ревматология: клинические рекомендации. Под ред. акад. РАМН Е.Л. Насонова. 2-е изд. испр. и доп. М.: ГЕОТАР-Медиа; 2010:523-557.
  2. Cutolo M, Straub RH. Stress as a risk factor in the pathogenesis of rheumatoid arthritis. Neuroimmunomodulation. 2006;13(5-6): 277-282. doi: 10.1159/000104855
  3. Сhen Y, Huang JZ, Qiang Y, Wang J, Han MM. Investigation of stressful life events in patients with systemic sclerosis. J Zhejiang Univ Sci B. 2008;9(11):853-856. doi: 10.1631/jzus.B0820069
  4. Vasile M, Valesini G, Riccieri V. Acute Stress: Is it a Risk Factor for the Development of Systemic Sclerosis? Ann Rheum Dis. 2015;74:1137. doi: 10.1136/annrheumdis-2015-eular.6067
  5. Лисицына Т.А., Вельтищев Д.Ю., Краснов В.Н., Насонов Е.Л. Клинико-патогенетические взаимосвязи иммуновоспалительных ревматических заболеваний и психических расстройств. Клиническая медицина. 2014;92(1):12-20.
  6. Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthrit Rheum. 1996;39(6):1035-1040. doi: 10.1002/art.1780390623
  7. Waheed A, Hameed K, Khan AM, Syed JA, Mirza AI. The burden of anxiety and depression among patients with chronic rheumatologic disorders at a tertiary care hospital clinic in Karachi, Pakistan. J Pak Med Assoc. 2006;56(5):243-246.
  8. Thombs BD, Hudson M, Taillefer SS, Baron M. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthrit & Rheum. 2008;59(4):504-509. doi: 10.1002/art.23524
  9. Mozzetta A, Antinone V, Alfani S, Neri P, Foglio Bonda PG, Pasquini P, Puddu P, Picardi A. Mental health in patients with systemic sclerosis: a controlled Investigation. J Eur Acad Dermatol Venereol. 2008;22(3):336-340. doi: 10.1111/j.1468-3083.2007.02426.x
  10. Mura G, Krishna M Bhat, Pisano A, Licci G, Carta M. Psychiatric Symptoms and Quality of Life in Systemic Sclerosis. Clinical Practice & Epidemiology in Mental Health. 2012;8(1):30-35. doi: 10.2174/1745017901208010030
  11. Baubet T., Ranque B, Taïeb O, Bérezné A, Bricou O, Mehallel S, Moroni Ch, Belin C, Pagnoux Ch, Moro M, Guillevin L, Mouthon L. Mood and anxiety disorders in systemic sclerosis patients. Presse Med. 2011;40:e111-e119. doi: 10.1016/j.lpm.2010.09.019
  12. Baubet T, Brunet M, Garcia De La Peña-Lefebvre P, Taïeb O, Moro MR, Guillevin L, Mouthon L. Psychiatric manifestations of systemic sclerosis. Ann Med Interne. 2002;153(4):237-341.
  13. Matsuura E, Ohta A, Kanegae F, Haruda Y, Ushiyama O, Koarada S, Togashi R, Tada Y, Suzuki N, Nagasawa K. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol. 2003;30:1782-1787.
  14. Beretta L, Astori S, Ferrario E, Caronni M, Raimondi M, Scorza R. Determinants of depression in 111 Italian patients with systemic sclerosis. Reumatismo. 2006;58(3):219-225. doi: 10.4081/reumatismo.2006.219
  15. Thombs BD, Taillefer SS, Hudson M, Baron M. Depression in patients with systemic sclerosis: A systematic review of the evidence. Arthrit Rheum. 2007;57(6):1089-1097. doi: 10.1002/art.22910
  16. Thombs BD, Fuss S, Hudson M, Schieir O, Taillefer SS, Fogel J, Ford DE, Baron M. High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. Arthrit Rheum. 2008;59(3):431-437. doi: 10.1002/art.23328
  17. Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, Boling Ch, Reed J, White B, Wigley FM. The impact of pain and symptoms of depression in scleroderma. Pain. 2002;95(3):267-275. doi: 10.1016/s0304-3959(01)00409-2
  18. Danieli E, Airò P, Bettoni L, Cinquini M, Antonioli Ch.M., Cavazzana I, Franceschini F, Cattaneo R. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol. 2005;24:48-54. doi: 10.1007/s10067-004-0970-z
  19. Bell C, Coupland N, Creamer P. Digital infarction in a patient with Raynaud’s phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report. Angiology. 1996;47:901-903. doi: 10.1177/000331979604700909
  20. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud’ s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology Oxford. 2001;40(9):1038-1043. doi: 10.1093/rheumatology/40.9.1038
  21. Hannestad J, Della Gioia N, Bloch M. The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis. Neuropsychopharmacology. 2011;36 (12):2452-2459. doi: 10.1038/npp.2011.132
  22. Masi AT. Subcommittee for scleroderma criteria of the American Rhеumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rhеum. 1980;23(5):581-590. doi: 10.1002/art.1780230510
  23. Jordan S, Maurer B, Toniolo M, Michel B, Distler O. Performance of the new EULAR /ACR classification criteria for systemic sclerosis in clinical practice. Ann Rhеum Dis. 2013;72(Suppl.3):60. doi: 10.1136/annrheumdis-2013-eular.239
  24. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol. 2003;21(3,Suppl.29):S39-S41.
  25. Montgomery SA, Asberg MA. New depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. doi: 10.1192/bjp.134.4.382
  26. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. doi: 10.1111/j.2044-8341.1959.tb00467.x
  27. Лурия A.P. Высшие корковые функции человека. М.; 1962.
  28. Драгунская Л.С. Изучение признаков депрессивных состояний методом «Пиктограммы». Экспериментальные исследования в патопсихологии. М.; 1976:167-174.
  29. Ковина Т.Е., Колеченко А.К., Агафонова И.Н. Коммуникативная культура и ее экспертиза. Ком. по образованию Санкт-Петербурга, С.-Петерб. ун-т пед. мастерства. СПб.: Б. и., 1996.
  30. Зейгарник Б.В. Нарушения мышления у психически больных. М.; 1958.
  31. Рубинштейн С.Я. Экспериментальные методики патопсихологии и опыт применения их в клинике. М.: 2004.
  32. Зейгарник Б.В. Патология мышления. М., 1962.
  33. Heim C, Nemeroff С. The Role of Childhood Trauma in the Neurobiology of Mood and Anxiety Disorders: Preclinical and Clinical Studies. Biol Psychiatry. 2001;49(12):1023-1039. doi: 10.1016/s0006-3223(01)01157-x
  34. Вельтищев Д.Ю., Марченко А.С., Серавина О.Ф., Ковалевская О.Б., Лисицына Т.А. Аффективно-стрессовая модель депрессии: практическое внедрение в ревматологической практике. Психиатрия и психофармакотерапия. 2009;11(5):17-22.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies